2026 Q3 - tulosraportti
23 päivää sitten
‧29 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 3 | ||
| 18 | ||
| 9 | ||
| 173 | ||
| 418 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 20.1.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 15.10. | ||
2026 Q2 - tulosraportti 9.7. | ||
2026 Q1 - tulosraportti 15.4. | ||
2025 Q4 - tulosraportti 21.1. | ||
2025 Q3 - tulosraportti 22.10.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·2 päivää sittenUpdated analysis 05.11.2026 Every time I buy – and I do that often – I think it cannot get any cheaper. But it has become just that until today, when I bought at 12,80 SEK. The "actual net asset value discount" in Flerie has now risen to no less than 78 % at today's closing price. This means that you get the unlisted shares at approx. 1/5 of the currently booked value. The official net asset value discount calculated by ibindex.se is a good 64 % d.d. and has never been higher. But note that I do not calculate the discount in the same way as ibindex, as I instead use what I term the actual net asset value discount. The "actual net asset value discount" I calculate solely in relation to the unlisted shares, as I first fully offset the value of the listed shares as well as positive capital incl. receivables (and offset any debt.) I have not included the purchase of Biosergen, but Flerie can only become better from that, and going forward this is the only way to be invested in Biosergen. But the purchase of Biosergen with payment in Flerie shares might perhaps contribute to selling pressure from former Biosergen shareholders right now on Flerie, which pushes the price down if they are not interested in being shareholders in Flerie, where Biosergen according to my calculation will "only" make up approx. 7 %. It is of course necessary to look at what unlisted shares are in the company's portfolio, and one must consider whether the value is correctly set. I do not have the prerequisites to know that, and I must therefore assess whether I find management and critics credible and competent, including to what degree management itself invests, and whether there are major investors who occasionally top up further. But - Mark Quick has on 23 October bought 10.779 shares in the investment company Flerie where he is part of the executive management as a partner. The shares were bought at the price of 14,88 kronor per share, a transaction of 160.400 kronor. Quick owned on 20 May 679.214 shares in Flerie, according to the ownership service Holdings. And - The investment company Flerie's CEO Ted Fjällman has on 16 to 21 October bought 28.221 shares in the company. The shares were bought at an average price of 15,28 kronor per share, a transaction of 431.200 kronor. This appears from the Swedish Financial Supervisory Authority's insider register. Fjällman is a major shareholder in Flerie. He thereafter owns 1,72 million shares, which corresponds to 1,98 percent of the capital and the votes, according to the ownership service Holdings. Why has the net asset value discount grown so enormously in 2026? The main reason as I see it is a totally opaque implemented attempt by the company's management to achieve the opposite, where the company in 2026 partly "distributed" a large part in cash to the shareholders, and where the main shareholder – which I have never experienced before – subsequently indirectly chipped into the cash register to the economic benefit of the other shareholders, who received additional shares for free. The result unfortunately became the exact opposite of the intentions. The net asset value discount grew exponentially instead of falling, as it objectively speaking should. The reason was that the chosen method was totally opaque for most shareholders. And also for the journalists who write about the stock market, and who ought to be wiser – which few of them are. On the contrary. This has meant that stock market journalists – and AI – consistently mention the previous year's net asset value for comparison with the current one, which is totally misleading. This incorrect comparison basis disappears in half a year's time, when "previous year's figures" going forward become truly comparable. But the damage is unfortunately done. Very few believe in the stock – and it will presumably take time before we reach back to the old net asset value discount, which just a year ago was down and hitting approx. 7 % (the official net asset value at Ibindex.se). If we ever get that far down again, as the historical price movement presumably scares most who do not know and cannot see through what actually happened in 2026. At the same time, I think I can note that Swedish small investors in general have become much less fond of investment companies – apart from just Investor. See e.g. Kinnevik. And specifically, that the interest for investing in the biotech sector via investment companies has been hit even harder – see e.g. Linc right now. Whether these two general conditions will change again – and to what extent and time frame that will happen – I have no opinion on when it concerns unlisted shares in the portfolios. The listed shares in the portfolio can be followed on the price list and discussion boards, so I will not address them here. But I invest in Flerie because of the misunderstood opaque redemption process in 2026, which I described above. Seen in relation to where Flerie's share price was compared to net asset value a year ago, a massive slip has occurred, without a corresponding known negative development having actually taken place in the underlying portfolio. But a year ago, shareholders were willing to pay more than double
·2.11.Have been following this for a while, really good net asset value discount right now.. Maybe time to enter? How do you reason? Of course a problem that the liquidity is quite low..
Forrest, I am indeed tempted due to the falling share price, but Flerie has over 20 different businesses going on, which will be time-consuming to get to grips with. I therefore have no idea what I am buying besides Biosergen and a couple of the companies that are listed. Is it a patchwork of bankruptcy estates or is it companies with great potential? I can only guess.
·2.11.What's up?Tjah? In Flerie, probably only good patience works. If you don't know what happened a little year ago and why we only get some other press releases and AI summaries when at least a year has passed since the misunderstood distribution to shareholders, read previous comments in this debate. And right now there are several small biotech companies that have taken a severe beating and several failed projects - so biotech is probably generally not valued very high, which can also rub off on Flerie despite the current huge net asset discount. But: "Mark Quick has on October 23 bought 10,779 shares in the investment company Flerie where he is part of the executive management as a partner. The shares were bought at the price of 14.88 SEK per share, a transaction of 160,400 SEK. The transaction was made on Nasdaq Stockholm. This appears from the Swedish Financial Supervisory Authority's insider register. Quick owned on May 20 679,214 shares in Flerie, according to the ownership service Holdings." and "Investment company Flerie's CEO Ted Fjällman has from October 16 to 21 bought 28,221 shares in the company. The shares were bought at an average price of 15.28 SEK per share, a transaction of 431,200 SEK. The transaction was made on Nasdaq Stockholm. This appears from the Swedish Financial Supervisory Authority's insider register. Fjällman is a larger owner in Flerie. He subsequently owns 1.72 million shares, which corresponds to 1.98 percent of the capital and votes, according to the ownership service Holdings."- ·23.10.Biosergen has just disappeared from my watchlist. I have read that they have applied for delisting and have merged with Flerie. Are any of you invested in Biosergen, and what does this mean now? Should one stay away from Flerie? I have not held shares in Biosergen, and therefore have not lost any shares or money. What does the panel think?"Som fusionsvederlag har Flerie emitterat cirka 2,67 miljoner nya stamaktier, vilket ökar aktiekapitalet med 5,9 miljoner kronor. Totalt har bolaget nu drygt 89,4 miljoner aktier." Biosergen udgør således nu ca. 7 % af Fleries unoterede portefølje.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
23 päivää sitten
‧29 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 päivää sittenUpdated analysis 05.11.2026 Every time I buy – and I do that often – I think it cannot get any cheaper. But it has become just that until today, when I bought at 12,80 SEK. The "actual net asset value discount" in Flerie has now risen to no less than 78 % at today's closing price. This means that you get the unlisted shares at approx. 1/5 of the currently booked value. The official net asset value discount calculated by ibindex.se is a good 64 % d.d. and has never been higher. But note that I do not calculate the discount in the same way as ibindex, as I instead use what I term the actual net asset value discount. The "actual net asset value discount" I calculate solely in relation to the unlisted shares, as I first fully offset the value of the listed shares as well as positive capital incl. receivables (and offset any debt.) I have not included the purchase of Biosergen, but Flerie can only become better from that, and going forward this is the only way to be invested in Biosergen. But the purchase of Biosergen with payment in Flerie shares might perhaps contribute to selling pressure from former Biosergen shareholders right now on Flerie, which pushes the price down if they are not interested in being shareholders in Flerie, where Biosergen according to my calculation will "only" make up approx. 7 %. It is of course necessary to look at what unlisted shares are in the company's portfolio, and one must consider whether the value is correctly set. I do not have the prerequisites to know that, and I must therefore assess whether I find management and critics credible and competent, including to what degree management itself invests, and whether there are major investors who occasionally top up further. But - Mark Quick has on 23 October bought 10.779 shares in the investment company Flerie where he is part of the executive management as a partner. The shares were bought at the price of 14,88 kronor per share, a transaction of 160.400 kronor. Quick owned on 20 May 679.214 shares in Flerie, according to the ownership service Holdings. And - The investment company Flerie's CEO Ted Fjällman has on 16 to 21 October bought 28.221 shares in the company. The shares were bought at an average price of 15,28 kronor per share, a transaction of 431.200 kronor. This appears from the Swedish Financial Supervisory Authority's insider register. Fjällman is a major shareholder in Flerie. He thereafter owns 1,72 million shares, which corresponds to 1,98 percent of the capital and the votes, according to the ownership service Holdings. Why has the net asset value discount grown so enormously in 2026? The main reason as I see it is a totally opaque implemented attempt by the company's management to achieve the opposite, where the company in 2026 partly "distributed" a large part in cash to the shareholders, and where the main shareholder – which I have never experienced before – subsequently indirectly chipped into the cash register to the economic benefit of the other shareholders, who received additional shares for free. The result unfortunately became the exact opposite of the intentions. The net asset value discount grew exponentially instead of falling, as it objectively speaking should. The reason was that the chosen method was totally opaque for most shareholders. And also for the journalists who write about the stock market, and who ought to be wiser – which few of them are. On the contrary. This has meant that stock market journalists – and AI – consistently mention the previous year's net asset value for comparison with the current one, which is totally misleading. This incorrect comparison basis disappears in half a year's time, when "previous year's figures" going forward become truly comparable. But the damage is unfortunately done. Very few believe in the stock – and it will presumably take time before we reach back to the old net asset value discount, which just a year ago was down and hitting approx. 7 % (the official net asset value at Ibindex.se). If we ever get that far down again, as the historical price movement presumably scares most who do not know and cannot see through what actually happened in 2026. At the same time, I think I can note that Swedish small investors in general have become much less fond of investment companies – apart from just Investor. See e.g. Kinnevik. And specifically, that the interest for investing in the biotech sector via investment companies has been hit even harder – see e.g. Linc right now. Whether these two general conditions will change again – and to what extent and time frame that will happen – I have no opinion on when it concerns unlisted shares in the portfolios. The listed shares in the portfolio can be followed on the price list and discussion boards, so I will not address them here. But I invest in Flerie because of the misunderstood opaque redemption process in 2026, which I described above. Seen in relation to where Flerie's share price was compared to net asset value a year ago, a massive slip has occurred, without a corresponding known negative development having actually taken place in the underlying portfolio. But a year ago, shareholders were willing to pay more than double
- ·2.11.Have been following this for a while, really good net asset value discount right now.. Maybe time to enter? How do you reason? Of course a problem that the liquidity is quite low..Forrest, I am indeed tempted due to the falling share price, but Flerie has over 20 different businesses going on, which will be time-consuming to get to grips with. I therefore have no idea what I am buying besides Biosergen and a couple of the companies that are listed. Is it a patchwork of bankruptcy estates or is it companies with great potential? I can only guess.
- ·2.11.What's up?Tjah? In Flerie, probably only good patience works. If you don't know what happened a little year ago and why we only get some other press releases and AI summaries when at least a year has passed since the misunderstood distribution to shareholders, read previous comments in this debate. And right now there are several small biotech companies that have taken a severe beating and several failed projects - so biotech is probably generally not valued very high, which can also rub off on Flerie despite the current huge net asset discount. But: "Mark Quick has on October 23 bought 10,779 shares in the investment company Flerie where he is part of the executive management as a partner. The shares were bought at the price of 14.88 SEK per share, a transaction of 160,400 SEK. The transaction was made on Nasdaq Stockholm. This appears from the Swedish Financial Supervisory Authority's insider register. Quick owned on May 20 679,214 shares in Flerie, according to the ownership service Holdings." and "Investment company Flerie's CEO Ted Fjällman has from October 16 to 21 bought 28,221 shares in the company. The shares were bought at an average price of 15.28 SEK per share, a transaction of 431,200 SEK. The transaction was made on Nasdaq Stockholm. This appears from the Swedish Financial Supervisory Authority's insider register. Fjällman is a larger owner in Flerie. He subsequently owns 1.72 million shares, which corresponds to 1.98 percent of the capital and votes, according to the ownership service Holdings."
- ·23.10.Biosergen has just disappeared from my watchlist. I have read that they have applied for delisting and have merged with Flerie. Are any of you invested in Biosergen, and what does this mean now? Should one stay away from Flerie? I have not held shares in Biosergen, and therefore have not lost any shares or money. What does the panel think?"Som fusionsvederlag har Flerie emitterat cirka 2,67 miljoner nya stamaktier, vilket ökar aktiekapitalet med 5,9 miljoner kronor. Totalt har bolaget nu drygt 89,4 miljoner aktier." Biosergen udgør således nu ca. 7 % af Fleries unoterede portefølje.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 3 | ||
| 18 | ||
| 9 | ||
| 173 | ||
| 418 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 20.1.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 15.10. | ||
2026 Q2 - tulosraportti 9.7. | ||
2026 Q1 - tulosraportti 15.4. | ||
2025 Q4 - tulosraportti 21.1. | ||
2025 Q3 - tulosraportti 22.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
23 päivää sitten
‧29 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 20.1.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 15.10. | ||
2026 Q2 - tulosraportti 9.7. | ||
2026 Q1 - tulosraportti 15.4. | ||
2025 Q4 - tulosraportti 21.1. | ||
2025 Q3 - tulosraportti 22.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 päivää sittenUpdated analysis 05.11.2026 Every time I buy – and I do that often – I think it cannot get any cheaper. But it has become just that until today, when I bought at 12,80 SEK. The "actual net asset value discount" in Flerie has now risen to no less than 78 % at today's closing price. This means that you get the unlisted shares at approx. 1/5 of the currently booked value. The official net asset value discount calculated by ibindex.se is a good 64 % d.d. and has never been higher. But note that I do not calculate the discount in the same way as ibindex, as I instead use what I term the actual net asset value discount. The "actual net asset value discount" I calculate solely in relation to the unlisted shares, as I first fully offset the value of the listed shares as well as positive capital incl. receivables (and offset any debt.) I have not included the purchase of Biosergen, but Flerie can only become better from that, and going forward this is the only way to be invested in Biosergen. But the purchase of Biosergen with payment in Flerie shares might perhaps contribute to selling pressure from former Biosergen shareholders right now on Flerie, which pushes the price down if they are not interested in being shareholders in Flerie, where Biosergen according to my calculation will "only" make up approx. 7 %. It is of course necessary to look at what unlisted shares are in the company's portfolio, and one must consider whether the value is correctly set. I do not have the prerequisites to know that, and I must therefore assess whether I find management and critics credible and competent, including to what degree management itself invests, and whether there are major investors who occasionally top up further. But - Mark Quick has on 23 October bought 10.779 shares in the investment company Flerie where he is part of the executive management as a partner. The shares were bought at the price of 14,88 kronor per share, a transaction of 160.400 kronor. Quick owned on 20 May 679.214 shares in Flerie, according to the ownership service Holdings. And - The investment company Flerie's CEO Ted Fjällman has on 16 to 21 October bought 28.221 shares in the company. The shares were bought at an average price of 15,28 kronor per share, a transaction of 431.200 kronor. This appears from the Swedish Financial Supervisory Authority's insider register. Fjällman is a major shareholder in Flerie. He thereafter owns 1,72 million shares, which corresponds to 1,98 percent of the capital and the votes, according to the ownership service Holdings. Why has the net asset value discount grown so enormously in 2026? The main reason as I see it is a totally opaque implemented attempt by the company's management to achieve the opposite, where the company in 2026 partly "distributed" a large part in cash to the shareholders, and where the main shareholder – which I have never experienced before – subsequently indirectly chipped into the cash register to the economic benefit of the other shareholders, who received additional shares for free. The result unfortunately became the exact opposite of the intentions. The net asset value discount grew exponentially instead of falling, as it objectively speaking should. The reason was that the chosen method was totally opaque for most shareholders. And also for the journalists who write about the stock market, and who ought to be wiser – which few of them are. On the contrary. This has meant that stock market journalists – and AI – consistently mention the previous year's net asset value for comparison with the current one, which is totally misleading. This incorrect comparison basis disappears in half a year's time, when "previous year's figures" going forward become truly comparable. But the damage is unfortunately done. Very few believe in the stock – and it will presumably take time before we reach back to the old net asset value discount, which just a year ago was down and hitting approx. 7 % (the official net asset value at Ibindex.se). If we ever get that far down again, as the historical price movement presumably scares most who do not know and cannot see through what actually happened in 2026. At the same time, I think I can note that Swedish small investors in general have become much less fond of investment companies – apart from just Investor. See e.g. Kinnevik. And specifically, that the interest for investing in the biotech sector via investment companies has been hit even harder – see e.g. Linc right now. Whether these two general conditions will change again – and to what extent and time frame that will happen – I have no opinion on when it concerns unlisted shares in the portfolios. The listed shares in the portfolio can be followed on the price list and discussion boards, so I will not address them here. But I invest in Flerie because of the misunderstood opaque redemption process in 2026, which I described above. Seen in relation to where Flerie's share price was compared to net asset value a year ago, a massive slip has occurred, without a corresponding known negative development having actually taken place in the underlying portfolio. But a year ago, shareholders were willing to pay more than double
- ·2.11.Have been following this for a while, really good net asset value discount right now.. Maybe time to enter? How do you reason? Of course a problem that the liquidity is quite low..Forrest, I am indeed tempted due to the falling share price, but Flerie has over 20 different businesses going on, which will be time-consuming to get to grips with. I therefore have no idea what I am buying besides Biosergen and a couple of the companies that are listed. Is it a patchwork of bankruptcy estates or is it companies with great potential? I can only guess.
- ·2.11.What's up?Tjah? In Flerie, probably only good patience works. If you don't know what happened a little year ago and why we only get some other press releases and AI summaries when at least a year has passed since the misunderstood distribution to shareholders, read previous comments in this debate. And right now there are several small biotech companies that have taken a severe beating and several failed projects - so biotech is probably generally not valued very high, which can also rub off on Flerie despite the current huge net asset discount. But: "Mark Quick has on October 23 bought 10,779 shares in the investment company Flerie where he is part of the executive management as a partner. The shares were bought at the price of 14.88 SEK per share, a transaction of 160,400 SEK. The transaction was made on Nasdaq Stockholm. This appears from the Swedish Financial Supervisory Authority's insider register. Quick owned on May 20 679,214 shares in Flerie, according to the ownership service Holdings." and "Investment company Flerie's CEO Ted Fjällman has from October 16 to 21 bought 28,221 shares in the company. The shares were bought at an average price of 15.28 SEK per share, a transaction of 431,200 SEK. The transaction was made on Nasdaq Stockholm. This appears from the Swedish Financial Supervisory Authority's insider register. Fjällman is a larger owner in Flerie. He subsequently owns 1.72 million shares, which corresponds to 1.98 percent of the capital and votes, according to the ownership service Holdings."
- ·23.10.Biosergen has just disappeared from my watchlist. I have read that they have applied for delisting and have merged with Flerie. Are any of you invested in Biosergen, and what does this mean now? Should one stay away from Flerie? I have not held shares in Biosergen, and therefore have not lost any shares or money. What does the panel think?"Som fusionsvederlag har Flerie emitterat cirka 2,67 miljoner nya stamaktier, vilket ökar aktiekapitalet med 5,9 miljoner kronor. Totalt har bolaget nu drygt 89,4 miljoner aktier." Biosergen udgør således nu ca. 7 % af Fleries unoterede portefølje.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 3 | ||
| 18 | ||
| 9 | ||
| 173 | ||
| 418 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt